

including public filing with a court, to the extent that disclosure of the information is relevant and necessary to the litigation or discussions and except where court orders are otherwise required under section (b)(11) of the Privacy Act of 1974, 5 U.S.C. 552a(b)(11).

L. Disclosure to Labor Unions

Information from this system of records may be disclosed to provide information to officials of labor organizations when relevant and necessary to their duties of exclusive representation concerning personnel policies, practices, and matters affecting work conditions.

Appendix B: Government-Wide Systems Notices Applicable to the Commission

The Commission maintains some records covered by Government-wide systems of records notices published by other agencies. There may not be actual Commission files in all Government-wide systems. This list is based on Privacy Act Issuances, 2003 Compilation, available at http://www.gpoaccess.gov/privacyact/2003.html. Any later established Government-wide systems notices may also be applicable.

- 1. DOL/GOVT-1 Federal Employees' Compensation Act File.
2. DOL/GOVT-2 Jobs Corps Student Records.
3. EEOC/GOVT-1 Equal Employment Opportunity in the Federal Government Complaint and Appeal Records.
4. FEMA/GOVT-1 National Defense Executive Reserve System.
5. GSA/GOVT-2 Employment Under Commercial Activities Contracts.
6. GSA/GOVT-3 Travel Charge Card Program.
7. GSA/GOVT-4 Contracted Travel Service Program.
8. GSA/GOVT-5 Access Certificates for Electronic Services.
9. MSPB/GOVT-1 Appeals and Case Records.
10. OGE/GOVT-1 Executive Branch Personnel Public Financial Disclosure Reports and Other Name-Retrieved Ethics Program Records.
11. OGE/GOVT-2 Executive Branch Confidential Financial Disclosure Reports.
12. OPM/Central-1 Civil Service Retirement and Insurance Records.
13. OPM/Central-2 Complaints and Inquiries Records.
14. OPM/Central-5 Intergovernmental Personnel Act Assignment Records.
15. OPM/Central-6 Administrative Law Judge Application Records.
16. OPM/Central-7 Litigation and Claims Records.
17. OPM/Central-9 Personnel Investigations Records.
18. OPM/Central-10 Federal Executive Institute Program Participant Records.
19. OPM/Central-11 Presidential Management Intern (PMI) Program Records.
20. OPM/Central-13 Executive Personnel Records.
21. OPM/GOVT-1 General Personnel Records.
22. OPM/GOVT-2 Employee Performance File System Records.

- 23. OPM/GOVT-3 Records of Adverse Actions, Performance Based Reduction in Grade and Removal Actions, and Termination of Probationers.
24. OPM/GOVT-5 Recruiting, Examining, and Placement Records.
25. OPM/GOVT-6 Personnel Research and Test Validation Records.
26. OPM/GOVT-7 Applicant Race, Sex, National Origin, and Disability Status Records.
27. OPM/GOVT-9 File on Position Classification Appeals, Job Grading Appeals, and Retained Grade or Pay Appeals, and Fair Labor Standard Act (FLSA) Claims and Complaints.
28. OPM/GOVT-10 Employee Medical File System Records.

Issued: June 13, 2006.
By order of the Commission.

Marilyn R. Abbott,

Secretary to the Commission.

[FR Doc. 06-5523 Filed 6-16-06; 8:45 am]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on January 20, 2006, Aptuit, 10245 Hickman Mills Drive, Kansas City, Missouri 64137, made application by letter to the Drug Enforcement Administration (DEA) for registration as an importer of a Cocaine derivative under the drug code for Cocaine (9041), a basic class of controlled substance in Schedule II.

The company plans to import bulk capsules in dosage form specifically for packaging for a clinical trial study.

Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to

the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than July 19, 2006.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substance listed in Schedule I or II are, and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 301.34(b), (c), (d), (e) and (f) are satisfied.

Dated: June 12, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E6-9511 Filed 6-16-06; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 11, 2005, Cedarburg Pharmaceutical, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II:

Table with 2 columns: Drug, Schedule. Rows include Tetrahydrocannabinols (7370), Dihydromorphine (9145), Methylphenidate (1724), Oxycodone (9193), Hydromorphone (9150), and Hydrocodone (9193).

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than August 18, 2006.

Dated: June 9, 2006.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E6-9508 Filed 6-16-06; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated January 11, 2006, and published in the **Federal Register** on January 23, 2006 (71 FR 3543), Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II:

Drug	Schedule
Cathinone (1235) .....	I
Methcathinone (1237) .....	I
N-Ethylamphetamine (1475) .....	I
N,N-Dimethylamphetamine (1480) .....	I
Aminorex (1585) .....	I
4-Methylaminorex (cis isomer) (1590) .....	I
Gamma Hydroxybutyric acid (2010) .....	I
Methaqualone (2565) .....	I
Alpha-Ethyltryptamine (7249) .....	I
Lysergic acid diethylamide (7315) .....	I
Marihuana (7360) .....	I
Tetrahydrocannabinols (7370) .....	I
Mescaline (7381) .....	I
3,4,5-Trimethoxyamphetamine (7390) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7391) .....	I

Drug	Schedule	Drug	Schedule
4-Bromo-2,5-dimethoxyphenethylamine (7392) .....	I	1-Phenylcyclohexylamine (7460) .....	II
4-Methyl-2,5-dimethoxyamphetamine (7395) .....	I	Phencyclidine (7471) .....	II
2,5-Dimethoxyamphetamine (7396) .....	I	1-Piperidinocyclohexanecarbonitrile (8603) .....	II
2,5-Dimethoxy-4-ethylamphetamine (7399) .....	I	Alphaprodine (9010) .....	II
3,4-Methylenedioxyamphetamine (7400) .....	I	Cocaine (9041) .....	II
5-Methoxy-3,4-methylenedioxyamphetamine (7401) .....	I	Codeine (9050) .....	II
N-Hydroxy-3,4-methylenedioxyamphetamine (7402) .....	I	Dihydrocodeine (9120) .....	II
3,4-Methylenedioxy-N-ethylamphetamine (7404) .....	I	Oxycodone (9143) .....	II
3,4-Methylenedioxy-N-methylamphetamine (7405) .....	I	Hydromorphone (9150) .....	II
4-Methoxyamphetamine (7411) .....	I	Diphenoxylate (9170) .....	II
Bufotenine (7433) .....	I	Benzoylcegonine (9180) .....	II
Diethyltryptamine (7434) .....	I	Ethylmorphine (9190) .....	II
Dimethyltryptamine (7435) .....	I	Hydrocodone (9193) .....	II
Psilocybin (7437) .....	I	Levomethorphan (9210) .....	II
Psilocyn (7438) .....	I	Levorphanol (9220) .....	II
Acetyldihydrocodeine (9051) .....	I	Isomethadone (9226) .....	II
Benzylmorphine (9052) .....	I	Meperidine (9230) .....	II
Codeine-N-oxide (9053) .....	I	Methadone (9250) .....	II
Dihydromorphine (9145) .....	I	Methadone intermediate (9254) .....	II
Heroin (9200) .....	I	Dextropropoxyphene, bulk (non-dosage forms) (9273) .....	II
Hydromorphanol (9301) .....	I	Morphine (9300) .....	II
Methylhydromorphanol (9304) .....	I	Thebaine (9333) .....	II
Morphine-N-oxide (9307) .....	I	Levo-alphaacetylmethadol (9648) .....	II
Normorphine (9313) .....	I	Oxymorphone (9652) .....	II
Pholcodine (9314) .....	I	Noroxymorphone (9668) .....	II
Acetylmethadol (9601) .....	I	Racemethorphan (9732) .....	II
Allylprodine (9602) .....	I	Alfentanil (9737) .....	II
Alphacetylmethadol except levo-alphaacetylmethadol (9603) .....	I	Sufentanil (9740) .....	II
Alphameprodine (9604) .....	I	Fentanyl (9801) .....	II
Alphamethadol (9605) .....	I		
Betacetylmethadol (9607) .....	I		
Betameprodine (9608) .....	I		
Betamethadol (9609) .....	I		
Betaprodine (9611) .....	I		
Hydroxypethidine (9627) .....	I		
Noracymethadol (9633) .....	I		
Norlevorphanol (9634) .....	I		
Normethadone (9635) .....	I		
Trimeperidine (9646) .....	I		
Phenomorphane (9647) .....	I		
Para-Fluorofentanyl (9812) .....	I		
3-Methylfentanyl (9813) .....	I		
Alpha-Methylfentanyl (9814) .....	I		
Acetyl-alpha-methylfentanyl (9815) .....	I		
Beta-hydroxyfentanyl (9830) .....	I		
Beta-hydroxy-3-methylfentanyl (9831) .....	I		
Alpha-Methylthiofentanyl (9832) .....	I		
3-Methylthiofentanyl (9833) .....	I		
Thiofentanyl (9835) .....	I		
Amphetamine (1100) .....	II		
Methamphetamine (1105) .....	II		
Phenmetrazine (1631) .....	II		
Methylphenidate (1724) .....	II		
Amobarbital (2125) .....	II		
Pentobarbital (2270) .....	II		
Secobarbital (2315) .....	II		
Glutethimide (2550) .....	II		
Nabilone (7379) .....	II		

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cerilliant Corporation to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cerilliant Corporation to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: June 12, 2006.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E6-9504 Filed 6-16-06; 8:45 am]

**BILLING CODE 4410-09-P**